New hope for pharmacogenetic testing.
Nurnberger
John I
JI
D001714:Bipolar Disorder / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics*; D003919:Diabetes Insipidus / Q000139:chemically induced; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000139:chemically induced; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use*; D010597:Pharmacogenetics / Q000379:methods*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011596:Psychomotor Disorders / Q000139:chemically induced; D018091:Receptors, AMPA / Q000235:genetics
D018091:Receptors, AMPA; D016651:Lithium Carbonate; C104722:glutamate receptor ionotropic, AMPA 2